bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-06-14: Clinical relevance and biological properties of oligometastatic breast cancer in lung; prognostic impact of CD44+/CD24−/low cells
Authors: Mimoto Rei , Kobayashi Tadashi , Imawari Yoshimi , Kamio Makiko , Kato Kumiko , Nogi Hiroko , Toriumi Yasuo , Uchida Ken , Takeyama Hiroshi 
Published: May 2015

Abstract
Background: Metastatic breast cancer is a systemic disease. Our aim was to evaluate the clinical outcomes of pulmonary metastasectomy of recurrent breast tumors and to identify possible prognostic factors.
Methods: We reviewed data from a registry of patients with lung metastases from breast tumors who received pulmonary metastasectomy in Jikei University Hospital between 2004 and 2011. We analyzed prognostic factors for overall survival (OS) and progression free survival (PFS) after metastasectomy. We also investigated lung metastases for the prevalence of CD44+/CD24−/low tumor cells and evaluated their prognostic significance.
Results: Among 17 patients with lung metastasis of breast tumors, 5-year OS and PFS were 72% and 36%, respectively. Better OS was observed among patients with oligometastatic breast cancer (OMBC). Patients with OMBC, estrogen receptor (ER) positive cells, and disease free intervals (DFI) of &gt;8 years had better PFS. The average prevalence of CD44+/CD24−/low tumor cells in lung metastases of breast cancer was 21%, ranging from 0 to 90%. The presence of CD44+/CD24−/low tumor cells influenced the progression after lung metastasectomy, with median PFS times of only 6 months in patients with high-prevalence of cancer-initiating cells. CD44+/CD24−/low cells with cancer-initiating properties were present in only 9% ± 12 of patients with OMBC but were found in 73% ± 21 of patients with non-OMBC.
Conclusion: Pulmonary metastasectomy may be a treatment option for OMBC patients with lung metastases. Better prognosis of OMBC may be related to low levels of cancer-initiating cells.
Citation Format: Rei Mimoto, Tadashi Kobayashi, Yoshimi Imawari, Makiko Kamio, Kumiko Kato, Hiroko Nogi, Yasuo Toriumi, Ken Uchida, Hiroshi Takeyama. Clinical relevance and biological properties of oligometastatic breast cancer in lung; prognostic impact of CD44+/CD24−/low cells [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-06-14.
Abstract P2-07-03: Pax-5 regulates EMT and MET in breast cancer through FAK1 regulation
Authors: Benzina Sami , O'Brien Pierre , Beauregard Annie-Pier , Guérrette Roxann , Jean Stéphanie , Robichaud Gilles 
Published: May 2015

Abstract
Metastasis accounts for 90% of deaths in breast cancers patients. Therefore, the study of genetic factors regulating cancer malignancy is a top priority to mitigate the morbidity and mortality associated to this disease. One of these factors, Pax-5, normally regulates key biological functions such as cell viability, growth, and differentiation. However, an aberrant expression of this factor results in the development and progression of cancer.
In this study, we developed breast cancer cell models with conditioned expression of the Pax-5 to evaluate signaling pathways relevant to breast metastasis and cancer progression. We found that Pax-5 extinguishes several aspects of cancer aggressivety such as: proliferation, spheroid formation, migration and invasion. At the molecular level, we found that Pax-5 modulates cancer malignancy through the regulation of various components of the epithelial to mesenchymal transitioning (EMT) process in addition to key signaling targets such as: NFκB and the Focal Adhesion Kinase 1 (FAK1). We also demonstrate that Pax-5 decreases FAK1 level trough up-regulation of miR-135b, a direct repressor of FAK1 expression. Altogether, our findings suggest that the presence of the Pax-5 lead to less aggressive breast cancers by promoting mesenchymal to Epithelial transitioning (MET). These findings bring light to molecular mechanisms driving breast cancer malignancy and benefit our quest in the development of diagnostic and therapeutic strategies against breast cancer progression.
Citation Format: Sami Benzina, Pierre O'Brien, Annie-Pier Beauregard, Roxann Guérrette, Stéphanie Jean, Gilles Robichaud. Pax-5 regulates EMT and MET in breast cancer through FAK1 regulation [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-07-03.
Abstract P2-11-01: Treatment of metastatic breast cancer patients by community health practitioners: Practice pattern and competence assessments
Authors: Fagerlie Sara R , Heintz Alison , Haas Maureen 
Published: May 2015

Abstract
Background: The complexity of current treatment and management for patients with metastatic breast cancer continues to rise. The volume and pace of scientific advances make it challenging for the community practitioner to stay abreast of optimal patient care. Education is key in disseminating critical information to practitioners and allows professional reflection of appropriate therapeutic decision making and peer discussion. Understanding the base knowledge, competence, and current practice patterns of the community practitioner is critical to identification community needs and implementation of education that impacts patient care.
Methods: During 2013 and 2014, educational outcomes assessments were gathered during 2 education programs consisting of 47 live independent continuing medical education (CME) activities held within community practices across the USA. Participants were asked a series of case-based questions via an audience response system to assess baseline knowledge, competence, and identify practice patterns Assessments were repeated following the 1-hour CME certified activity. Long-term assessment was conducted electronically 6-weeks following the educational initiative.
Results: The programs educated 958 practitioners, including 515 physicians. Practice patterns for frontline treatment varied at baseline. Education resulted in treatment more highly aligned with practice guidelines and recent advances. At baseline 75% of practitioners and 30% of the physician target audience were unable to identify appropriate next steps in a borderline HER2+ patient. The education reduced the gap by 25%. 6-weeks following the activity 100% of the assessed physician target audience agreed or strongly agreed that the education influenced their interpretation of HER2 testing. Practice gaps in practitioners ability to identify, recall, and interpret practice changing clinical trials were also identified. Newness of treatment data, lack of reimbursement, and treatment side effects were the most common barriers identified in applying the education into clinical practice.
Conclusions: The results highlight the diversity of current clinical practice in the community practice setting for patients with metastatic breast cancer and the positive impact of focused education. Knowledge and competence practice gaps were identified to pinpoint specific areas of benefit for the community practice setting in the treatment of patients with metastatic breast cancer.
Citation Format: Sara R Fagerlie, Alison Heintz, Maureen Haas. Treatment of metastatic breast cancer patients by community health practitioners: Practice pattern and competence assessments [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-11-01.
Abstract P2-12-09: Psycho-oncological intervention in breast cancer patients - A quantitative analysis of tumor associated fatigue treatment
Authors: Eichler Christian , Multhaupt Pia , Multhaupt Sibylle , Wolff Friedrich , Warm Mathias 
Published: May 2015

Abstract
Abstract
Background: Although tumor associated fatigue (TAF) or cancer related fatigue (CRF) is not a new concept, no real headway has been made in the quantitative analysis of its successful treatment. Since 20 to 30% of all breast cancer patients suffer from anxiety and/or depression within the first year of their diagnosis, this issue needs to be addressed and a standard treatment protocol has to be developed. Multimodal approaches are currently being used including increased physical activity, pharmaceutical therapy, and psycho-oncological intervention. This study focused on developing a simple, reproducible protocol for the psycho-oncological support of tumor associated fatigue patients.
Methods: Between the year 2011 and 2012, 23 breast cancer patients fulfilled the diagnosis TAF requirements and were introduced into this study. All patients had received surgery and were currently being monitored in an adjuvant setting. Our method focused on a psycho-oncological support group using a predetermined, highly structured and reproducible treatment manual. Eight weekly, 90 minute sessions were conducted and patients were evaluated before and after this eight session block. Tumor fatigue specific questionnaires such as the multidimensional fatigue inventory (MFI) as well as the hospital anxiety and depression scale (HADS) were used in order to quantitatively evaluate patient TAF.
Results: Of the 23 patients enrolled in the study, only 7 patients fulfilled the TAF diagnostic criteria after the psycho-oncological group treatment. This represents a 70% reduction in diagnosable tumor associated fatigue. The HADS analysis showed a 33% reduction in patient anxiety as well as a 57% reduction in patient depression levels. The MFI scores showed a significant reduction in 4 of the 5 evaluate categories. With the exception of the "mental fatigue" MFI category all results were statistically significant.
Conclusion: This study showed that a highly structured, psycho-oncological group intervention will produce significant improvements in breast cancer patient tumor associated fatigue levels after only 8 sessions. This type of group therapy should be recommended as a standard of care for all TAF breast cancer patients.
Citation Format: Christian Eichler, Pia Multhaupt, Sibylle Multhaupt, Friedrich Wolff, Mathias Warm. Psycho-oncological intervention in breast cancer patients - A quantitative analysis of tumor associated fatigue treatment [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-12-09.
Abstract P2-12-14: The effect of low intensity exercise for mental status and quality of life of Japanese early breast cancer patients
Authors: Kamio Makiko , Kawase Kazumi , Nogi Hiroko , Uchida Ken , Takeyama Hiroshi 
Published: May 2015

Abstract
Objective: Breast cancer is one of the most common cancers, and it accounts for 20% of malignant tumors of women. Psychological damage of the breast cancer patient is serious. In our institution, approximately 30% of the early breast cancer patients diagnosed as depressed mental status before operation. Breast cancer patients have to receive hormone therapy, chemotherapy, and radiation therapy for a long term after operation. Depressed mental status affects execution of the treatment, and the interruption of the treatment brings the risk of cancer recurrence. As a treatment for depressed mental status of cancer patients, medication and psychotherapy are common, but some previous reports showed exercise is effective. Exercises provided in these reports were various kinds and strength, and the standard prescription is not established. We investigate the effect of walking program as a mild aerobic exercise, whether it improves the depressed mental status and quality of life (QOL) of breast cancer patients.
Methods: 25 early breast cancer patients were recruited. Depressed mental status and QOL were assessed by Center for Epidemiologic Studies Depression Scale (CES-D) and Medical Outcomes Study 36-item Short Form Health Survey (SF-36). Physical activity was measured by accelerometer (Lifecorder PLUS, Suzuken), and estimated using metabolic equivalent foe task (MET). Participants mounted accelerometer after discharge, and baseline physical activity was recorded till 1 month after operation. After recording baseline physical activity, we instructed to perform walking or mild aerobic exercise. Scores of CES-D and SF-36, and physical activity data were measured again after two months.
Results: Physical activity after intervention was significantly increased as compared to baseline (8.5±5.5 vs 12.3±6.9 MET.h/week, p=0.02 ). At pre-operation phase, nine patients (36%) regarded as depressed mental status by CES-D, and depressed patients decreased to five at the time of 3 months after operation. A subscale of SF-36 ( mental health ) reduced significantly compared with pre-operation and 3 months after operation ( p&lt;0.01 ). Physical activity after intervention was correlated with the scores of CES-D and all subscales of SF-36.
Conclusion: This study demonstrated the possibility that walking program as a mild exercise improves mental status and QOL of perioperative breast cancer patients. It is necessary to examine in more detail for clinical application.
Citation Format: Makiko Kamio, Kazumi Kawase, Hiroko Nogi, Ken Uchida, Hiroshi Takeyama. The effect of low intensity exercise for mental status and quality of life of Japanese early breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-12-14.
Abstract P2-13-07: Prophylactic mastectomy in young women with breast cancer
Authors: Metran Nascente Cristiane , Wright Frances , Helwig Christel , Li Nim , Mandel Rodica , Kiss Alex , Warner Ellen 
Published: May 2015

Abstract
Background: In recent years women with unilateral breast cancer (BC) have been increasingly requesting contralateral or bilateral prophylactic mastectomy (PM) despite only requiring unilateral mastectomy (M) or lumpectomy (L) respectively. This trend has been observed even in women at low risk for contralateral BC, particularly among younger women.
Objective: Determine the rates of ‘unexplained’ PM (UPM) and factors associated with this choice, among a prospective cohort of newly diagnosed young women with BC at our centre.
Methods: We reviewed the records of all patients diagnosed with BC at age ≤ 40 years from Feb ‘08 to Sept ’13 at Sunnybrook who consented to have their clinical data entered in a prospective research database. Psychosocial data - HADS [Hospital Anxiety and Depression Scale] and IES [Impact of Event Scale] - were prospectively collected from all consenting women at baseline and at completion of active treatment. Among the 149 patients treated with curative intent, 43 received unilateral M, 59 L and 47 contralateral or bilateral PM. These groups were compared with respect to demographics, risk factors, use of pre-operative MRI, pathology, treatment and surgeon gender. Differences in variables between the groups were analyzed using analysis of variance for continuous variables and chi-square test for categorical variables.
Results: The mean age of all patients was 35 years old (21-40 range). Among the 47 patients who had PM, the first surgery was L for 15 (32%), unilateral M for 27 (57%) and bilateral M for 5 (11%). Twenty-four (51%) fulfilled high risk criteria (19 BRCA mutation, 4 strong family history, 1 chest radiation) and 2 (4%) had suspicious findings in the contralateral breast. The other twenty-one patients (45%) underwent UPM for "peace of mind" alone. Thirty-three (33%) of UPM patients had T3-4 tumors. There were no statistically significant differences between the UPM group and the combined M plus L groups, except for more multicentric/ multifocal disease in the UPM groups (43% vs 9% p≤0.0001).
Discussion: Fourteen percent of young women at our centre, a 1/3 with a relatively poor prognosis had UPM. Data correlating surgical choice with baseline and follow-up psychological variables will be presented. There appears to be a need for an educational/psychological intervention at the time of BC diagnosis for non-high-risk women contemplating preventive breast surgery to ensure that such a choice is truly informed.
Citation Format: Cristiane Metran Nascente, Frances Wright, Christel Helwig, Nim Li, Rodica Mandel, Alex Kiss, Ellen Warner. Prophylactic mastectomy in young women with breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-07.
Abstract P2-14-04: Is the combination of fat grafts and platelet rich plasma effective and safe? An experimental study in rats
Authors: Freitas-Junior Ruffo , Blumenschein Alexandre R , Moreira Marise AR , Cysneiros Maria-Auxiliadora PC , Pereira Roseana N 
Published: May 2015

Abstract
Autologous fat grafts and lipofilling can be used for breast reconstruction after breast conserving therapy. Fat is considered an ideal filler because of its low cost, ease of harvest, abundance in the human body and low immunogenic and allergic reaction due to its autologous nature. Platelet rich plasma (PRP) is a plasma fraction, with platelet count above baseline, generally obtained via centrifugation of blood. PRP theoretically promotes tissue regeneration due to fact that it concentrates a greater amount of growth factors essential in the process of tissue regeneration and neovascularization. This paper aims to examine if the association of fat grafts and PRP improves graft viability in female rats, through an experimental, randomized and blinded study, which involved 47 animals. These animals underwent fat graft harvest from their inguinal fat deposits and fat grafting subcutaneously to their cranial region. In 22 animals the fat graft was mixed with PRP and in 25 the fat was grafted by itself. After a 100 day period, the animals were sacrificed and the fat grafts were analyzed using scores from 0 (absent) to 4 (abundant), in optical microscopy by two independent and blinded pathologists, by means of the following variables: fat graft cell viability, fat necrosis, tissue inflammation and fibrosis. Regarding fat graft cell viability, the PRP group scored moderate/abundant in 63% of the cases and the fat graft only group scored absent/slight in 72% of the cases (p&lt;0.05). The PRP group presented lower fat necrosis scores and lower tissue inflammation scores when compared to the fat graft only group (p&lt;0.05). The presence of tissue fibrosis was rarely observed in both groups. Tumors (dermoid cysts) within the fat grafts were observed in 3 animals in which the grafts were mixed with PRP. It is concluded that PRP improves the viability and integration of fat grafts in rats, but more studies are needed to fully understand the exact mechanisms that lead to this improvement and assess the safety of the method for use in humans.
Citation Format: Ruffo Freitas-Junior, Alexandre R Blumenschein, Marise AR Moreira, Maria-Auxiliadora PC Cysneiros, Roseana N Pereira. Is the combination of fat grafts and platelet rich plasma effective and safe? An experimental study in rats [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-14-04.
Abstract P3-04-12: Pathological and molecular effects of lack of PR expression in ER positive breast tumors
Authors: Ellsworth Rachel E , Valente Allyson L , Hueman Matthew T , Shriver Craig D 
Published: May 2015

Abstract
Background: Evaluation of hormone receptor status is standard in breast cancer diagnosis; however, prognosis and treatment decisions are frequently based on the status of the estrogen receptor (ER) but not the progesterone receptor (PR). To determine how PR status affects etiology and outcome of ER positive tumors, pathological and molecular characteristics of ER+PR+ and ER+PR- tumors were assessed.
Methods: ER and PR positivity were defined as &gt;10% staining and all patients with ER+PR+ and ER+PR- were identified. Differences in pathological characteristics were evaluated using Chi-square tests with P&lt;0.05 defining significance. RNA was isolated from primary tumor cells after laser-microdissection and hybridized to U133A 2.0 arrays. Gene expression data was analyzed by ANOVA using a false-detection rate &lt;0.5 and &gt;2.0-fold difference to define significance.
Results: Of the 1,139 ER+ tumors, 21% were PR-. Age at diagnosis, ethnicity, tumor size, lymph node and Ki67 status did not differ between groups; however, patients with PR- tumors were significantly more likely to be diagnosed at an advanced stage, with high-grade, HER2 positive tumors, and more likely to die of disease. Thirty genes were differentially expressed including significantly higher expression levels of APOBEC3B and significantly lower expression of GREB1, MAPT and SCUBE2.
Discussion: Expression of PR significantly alters tumor biology and clinical outcomes of ER positive tumors. Genes with altered expression in PR negative tumors are associated with more aggressive characteristics, such as increased invasion, kataegis, regulation of ER and response to tamoxifen. Thus, PR status is critical in the diagnosis and treatment of patients with ER positive breast tumors.
Citation Format: Rachel E Ellsworth, Allyson L Valente, Matthew T Hueman, Craig D Shriver. Pathological and molecular effects of lack of PR expression in ER positive breast tumors [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-04-12.